REVENUE (Tables)

9 Months Ended

Sep. 30, 2026

Revenue by segment and geography based on shipped to locations for the three and nine months ended September 30, 2026 and 2025 were as follows:


	For the Three Months Ended September 30, 2026
Segment	Europe		Domestic		Latin America		Asia		Total
Pharma	$	215,218	$	151,570	$	20,108	$	67,074	$	453,970
Beauty	215,133		58,037		44,755		39,447		357,372
Closures	71,072		89,959		24,507		22,239		207,777
Total	$	501,423	$	299,566	$	89,370	$	128,760	$	1,019,119


	For the Three Months Ended September 30, 2025
Segment	Europe		Domestic		Latin America		Asia		Total
Pharma	$	208,055	$	157,606	$	10,968	$	68,781	$	445,410
Beauty	196,137		57,012		42,132		32,487		327,768
Closures	61,611		85,110		22,031		19,201		187,953
Total	$	465,803	$	299,728	$	75,131	$	120,469	$	961,131


	For the Nine Months Ended September 30, 2026
Segment	Europe		Domestic		Latin America		Asia		Total
Pharma	$	672,635	$	436,735	$	59,350	$	181,977	$	1,350,697
Beauty	659,187		175,145		133,221		120,908		1,088,461
Closures	201,486		259,493		67,827		60,531		589,337
Total	$	1,533,308	$	871,373	$	260,398	$	363,416	$	3,028,495


	For the Nine Months Ended September 30, 2025
Segment	Europe		Domestic		Latin America		Asia		Total
Pharma	$	618,577	$	460,429	$	36,469	$	181,991	$	1,297,466
Beauty	589,282		172,041		124,625		82,376		968,324
Closures	172,585		259,464		62,693		53,913		548,655
Total	$	1,380,444	$	891,934	$	223,787	$	318,280	$	2,814,445

The opening and closing balances of our contract asset and contract liabilities were as follows:


	Balance as of September 30, 2026		Balance as of December 31, 2025		Increase/ (Decrease)
Contract asset (current)	$	13,717	$	11,600	$	2,117

Contract liability (current)	82,763		74,827		7,936
Contract liability (long-term)	38,931		49,901		(10,970)